Objective: To reveal the mechanism and effect of SU5416 in the treatment of mouse Lewis cancer in vivo. Methods: Lewis cell was transplanted into groin of C57/B6 mouse by subcutaneous injection, then SU5416 was admini...Objective: To reveal the mechanism and effect of SU5416 in the treatment of mouse Lewis cancer in vivo. Methods: Lewis cell was transplanted into groin of C57/B6 mouse by subcutaneous injection, then SU5416 was administrated intraperitoneally to investigate the impact of SU5416 on tumor angiogenesis and growth in vivo. 32 mice were treated with SU5416 at two different doses every day until the end-point. As a control, 8 mice received no treatment and 8 mice were treated with vehicle (DMSO) only after implantation. Results: Median survival in the treated group was statistically longer compared to that in the control groups (P < 0.05) and no significant systemic adverse was observed. Histological analysis of the treated tumors showed an increase in necroses and reduced in angiogenesis compared to the control tumors. Furthermore, the percent of apoptotic cells increased in the treated tumors by FCM, the expressions of VEGF and KDR had no change after SU5416 administration by western blot. Conclusion: SU5416 may be useful therapeutics drug that specifically inhibits the enzymatic activity of KDR kinase and could down regulate the tumor angiogenesis.展开更多
基金a grant from the National Key Project of Scientific and Technical Supporting Programs funded by Ministry of Science & Technology of China (No. 2006BAI02A05).
文摘Objective: To reveal the mechanism and effect of SU5416 in the treatment of mouse Lewis cancer in vivo. Methods: Lewis cell was transplanted into groin of C57/B6 mouse by subcutaneous injection, then SU5416 was administrated intraperitoneally to investigate the impact of SU5416 on tumor angiogenesis and growth in vivo. 32 mice were treated with SU5416 at two different doses every day until the end-point. As a control, 8 mice received no treatment and 8 mice were treated with vehicle (DMSO) only after implantation. Results: Median survival in the treated group was statistically longer compared to that in the control groups (P < 0.05) and no significant systemic adverse was observed. Histological analysis of the treated tumors showed an increase in necroses and reduced in angiogenesis compared to the control tumors. Furthermore, the percent of apoptotic cells increased in the treated tumors by FCM, the expressions of VEGF and KDR had no change after SU5416 administration by western blot. Conclusion: SU5416 may be useful therapeutics drug that specifically inhibits the enzymatic activity of KDR kinase and could down regulate the tumor angiogenesis.
文摘目的比较单纯低氧与低氧联合SU5416建模方法的异同,探索低氧联合SU5416能否建立更显著的肺动脉高压小鼠模型。方法 15只雄性C57BL/6小鼠采用数字表法随机分为3组(每组5只):常氧组、单纯低氧组和低氧联合SU5416组,4周后,检测各组小鼠体质量(body weight,BW)、右心室收缩压(right ventricular systolic pressure,RVSP)、右心室肥厚指数(the index of right ventricular hypertrophy,RVHI)、右心室/体质量比值(right ventricle/body weight,RV/BW),并检测其肺小动脉的形态学改变以及血管中膜厚度占血管外径百分比(medial thickness,MT%)。结果 4周后,常氧组小鼠的体质量明显高于单纯低氧组和低氧联合SU5416组,单纯低氧组、低氧联合SU5416组小鼠的RVSP、RVHI、RV/BW、MT%均高于常氧组,且低氧联合SU5416组小鼠的RVSP、RVHI、MT%三项指标较单纯低氧组更高,而低氧联合SU5416组小鼠的RV/BW与单纯低氧组差异无统计学意义。结论低氧联合SU5416能建立比单纯低氧更显著的肺动脉高压小鼠模型。